Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

DNA nanorobots target HER2-positive breast cancer cells

According to the Mayo Clinic, about 20% of breast cancers make abnormally high levels of a protein called human epidermal growth factor receptor 2 (HER2).

When displayed on the surface of cancer cells, this signalling protein helps them proliferate uncontrollably and is linked with a poor prognosis.

Now, researchers have developed a DNA nanorobot that recognises HER2 on breast cancer cells, targeting them for destruction.

They report their results in the ACS journal Nano Letters.

Current therapies for HER2-positive breast cancer include monoclonal antibodies, such as trastuzumab, that bind to HER2 on cells and direct it to the lysosome -- an organelle that degrades biomolecules.

Lowering the levels of HER2 slows cancer cell proliferation and triggers cell death.

Although monoclonal antibodies can lead to the death of cancer cells, they have severe side effects and are difficult and expensive to produce.

In a previous study, Yunfeng Lin and colleagues identified a short sequence of DNA, called an aptamer, that recognises and binds HER2, targeting it for lysosomal degradation in much the same way that monoclonal antibodies do.

But the aptamer wasn't very stable in serum.

So the researchers wanted to see if adding a DNA nanostructure, called a tetrahedral framework nucleic acid (tFNA), could increase the aptamer's biostability and anti-cancer activity.

To find out, the team designed DNA nanorobots consisting of the tFNA with an attached HER2 aptamer.

When injected into mice, the nanorobots persisted in the bloodstream more than twice as long as the free aptamer.

Next, the researchers added nanorobots to three breast cancer cell lines in petri dishes, showing that they killed only the HER2-positive cell line.

The addition of the tFNA allowed more of the aptamer to bind to HER2 than without tFNA, leading to reduced HER2 levels on cell surfaces.

Although the nanorobot is much easier and less expensive to make than monoclonal antibodies, it likely needs further improvement before it could be used to treat breast cancer in the clinic, the researchers say.

Source: American Chemical Society

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation